Treatment Options in Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation

Abstract

Spanish

French

Objective:

To evaluate the treatment options in steroid-refractory acute graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation.

Data Sources:

Literature was obtained by searching MEDLINE (1966–May 2007) and EMBASE (1980–May 2007).

Study Selection and Data Extraction:

All pertinent clinical trials, retrospective studies, case reports, and compassionate use studies were identified and evaluated for safety and efficacy of the pharmacologic agents.

Data Synthesis:

Steroid-refractory acute GVHD is associated with high rates of morbidity and mortality. Although various pharmacologic agents have been studied in the treatment of steroid-refractory acute GVHD, no treatments have been established as a salvage therapy. Preliminary data on different pharmacologic agents have been identified and evaluated for their efficacy and tolerability in the treatment of steroid-refractory acute GVHD. The effects of the pharmacologic agents varied significantly among patients: severity of the disease, involvement of different organs, and the patient's age seem to be the major factors that affect an individual's response to drug therapy. In addition, the treatments are further challenged by the high incidence of potentially fatal opportunistic infections that occur during the therapy.

Conclusions:

Selection of pharmacologic agents for the treatment of steroid-refractory acute GVHD should be based on the target organs, adverse drug reactions, and economic factors. Further studies with larger sample sizes are warranted to better understand the roles of these agents in the treatment of steroid-refractory acute GVHD.

Keywords

hematopoietic stem cell transplantation steroid-refractory acute graft-versus-host disease

Get full access to this article

View all access options for this article.

References

Ferrara

JLM

Reddy

. Pathophysiology of graft versus host disease. Semin Hematol 2006;43:3–10. DOI 10.1053/j.seminhematol.2005.09.001

Glucksberg

Storb

Fefer

. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplant 1974;18:295–304.

Filipovich

Weisdorf

Pavletic

. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–56. DOI 10.1016/j.bbmt.2005.09.004

Przepiorka

Weisdorf

Martin

. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825–8.

Bacigalupo

Palandri

. Management of acute graft-versus-host disease. Hematol J 2004;5:189–96. DOI 10.1038/sj.thj.6200399

Goulmy

Schipper

Pool

. Mismatches of minor histocompatibility antigens between HLS-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281–5.

Kernan

Dupont

. Minor histocompatibility antigens and marrow transplantation. N Engl J Med 1996;334:323–4.

Ferrara

JLM

Levine

. Graft versus host disease in the 21st century: new perspectives on an old problem. Semin Hematol 2006;43:1–2. DOI 10.1053/j.seminhematol.2005.11.02

Deeg

. How I treat refractory acute GVHD. Blood 2007;109:4119–26. Epub 18 Jan 2007. DOI 10.1182/blood-2006-12-041889

10.

Jacobsohn

Vogelsang

. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002;62:879–89.

11.

Weisdorf

Haake

Blazar

. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990;75:1024–30.

12.

Couriel

Caldera

Champlin

Komanduri

. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004;101:1936–46. Epub 15 Sept 2004. DOI 10.1002/cncr.20613

13.

Van Lint

Uderzo

Locasciulli

. Early treatment of acute graft-versus-host disease with high or low dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation. Blood 1998;7:2288–93.

14.

Van Lint

Milone

Leotta

. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006;107:4177–81. Epub 31 Jan 2006. DOI 10.1182/blood-2005-12-4851

15.

Bolanos-Meade

Vogelsang

. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol 2005;12:40–4.

16.

Arai

Margolis

Zahurak

Anders

Vogelsang

. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002;8:155–60.

17.

Barry

Murphy

. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568–84.

18.

Ross

. Treatment of gastrointestinal acute graft-versus-host disease. Curr Treat Options Gastroenterol 2005;8:249–58.

19.

McCaul

Nevill

Barnett

. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000;9:367–74.

20.

Mayer

Krejci

Doubek

. Pulse cyclophosphamide for corti-costeroid-refractory graft versus host disease. Bone Marrow Transplant 2005;35:699–705. Epub 7 Feb 2005. DOI 10.1038/sj.bmt.1704829

21.

Kim

Sohn

Kim

. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:56–61.

22.

Takami

Mochizuki

Okumura

. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 2006;83:80–5. DOI 10.1532/IJH97.05111

23.

Krejci

Doubek

Buchler

Brychtova

Vorlicek

Mayer

. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005;84:681–5. Epub 7 Jul 2005. DOI 10.1007/s00277-005-1070-0

24.

Benito

Furlong

Martin

. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001;72:1924–9.

25.

Bolanos-Meade

Jacobsohn

Margolis

. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005;23:2661–8. DOI 10.1200/JCO.2005.06.130

26.

Zahrieh

Hochberg

. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:1224–6. Epub 27 Apr 2004. DOI 10.1182/blood-2004-01-0028

27.

Shaughnessy

Bachier

Grimley

. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:188–93. DOI 10.1016/j.bbmt2004.11.022

28.

Pinana

Valcarcel

Martino

. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Bio Blood Marrow Transplant 2006;12:1135–41. DOI 10.1016/j.bbmt.2006.06.010

29.

Massenkeil

Rackwitz

Genvresse

Rosen

Dorken

Arnold

. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:899–903. DOI 10.1038/sj.bmt.1703737

30.

Schmidt-Hieber

Fietz

Knauf

. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005;130:568–74.

31.

Bordigoni

Dimicoli

Clement

. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006;135:382–5. DOI 10.1111/j.1365-2141.2006.06321.x

32.

Busca

Locatelli

Marmont

. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82:45–52. Epub 25 Aug 2006. DOI 10.1002/ajh.20752

33.

Patriarca

Sperotto

Damiani

. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004;89:1352–9.

34.

Carpenter

Pavlovic

Tso

. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T-cells. J Immunol 2000;165:6205–13.

35.

Carpenter

Appelbaum

Corey

. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712–9.

36.

Carpenter

Lowder

Johnston

. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Bio Blood Marrow Transplant 2005;11:465–71. DOI 10.1016/j.bbmt.2005.03.002

37.

Carella

Beltrami

Scalzulli

Carella

Corsetti

. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (letter). Bone Marrow Transplant 2004;33:131–2. Epub 20 Oct 2003. DOI 10.1038/sj.bmt.1704322

38.

Wandroo

Auguston

Cook

Craddock

Mahendra

. Successful use of campath-1H in the treatment of steroid refractory liver GVHD (letter). Bone Marrow Transplant 2004;34:285–7. Epub 31 May 2004. DOI 10.1038/sj.bmt.1704573

39.

Fleming

. Redbook 2007: pharmacy's fundamental reference. Andover, Hampshire, England: Thompson, 2007.